DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
ECCO '19 Copenhagen
2019
DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
ECCO '19 Copenhagen
2019
DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
ECCO '19 Copenhagen
2019
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
ECCO '19 Copenhagen
2019
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
ECCO '19 Copenhagen
2019
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC
ECCO '19 Copenhagen
2019
DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
ECCO '19 Copenhagen
2019
DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s
ECCO '19 Copenhagen
2019
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
ECCO '19 Copenhagen
2019
DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease
ECCO '19 Copenhagen
2019
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort studyECCO '19 Copenhagen
2019
DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?
ECCO '19 Copenhagen
2019
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019